Introduction
============

It is well known that hypertension has become a major public health problem which needs to be urgently addressed in the world. Commonly, average blood pressure (BP) level is widely recommended by clinical guidelines to be a key component in the management of CVD ([@ref1]--[@ref2]). However, recent evidences have shown that the protective effect of antihypertension depends on not only reductions in average BP levels but also visit-to-visit variability (VVV) in BP ([@ref3]--[@ref7]). VVV in systolic (S) BP has a strong predictor for cardiovascular events, stoke, and renal dysfunction in patients with on-treated hypertension and in patients with a previous transient ischemic attack, independent of mean BP ([@ref3]). Moreover, it is also associated with increased all-cause mortality independently of age, sex, and average SBP levels ([@ref6]). Therefore, VVV in BP may be another critical goal besides average BP lowering in management of hypertensive patients.

VVV in SBP has been verified to be consistent within individuals over time and can be well reproducible ([@ref8]). It was correlated with 24-h ABP variability in the Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA) study ([@ref3]). ABP variability is independently related to arterial stiffness ([@ref9]), endothelial function ([@ref10]). From these standpoints, we hypothesized that VVV in BP might be also associated with atherosclerosis and endothelial function. However, to the best of our knowledge, the association of VVV in BP with the progression of atherosclerosis and endothelial dysfunction is also obscured. To elucidate the hypothesis maybe significantly reduce the cardiovascular morbidity and mortality. It will be benefit for the majority of hypertensive patients and reduce the health burden of family and society. Accordingly, at least in some extent, management of VVV in BP will promote the settlement of issues related to public health.

In the present study, our major goal was to investigate the relationship of between VVV in SBP and the progression of carotid atherosclerosis and stiffness and endothelial dysfunction in on-treated essential hypertensive patients.

Materials and Methods
=====================

Study Design and Patients
-------------------------

This study was conducted as part of the Chinese Hypertension Intervention Efficacy (CHIEF) study. The design and methods of CHIEF have been reported previously ([@ref11]--[@ref12]). From May 2008 and October 2012, we initially recruited 372 hypertensive patients from clinics in rural area of Shandong, China. The mean age was 54.04 ± 7.10 years (range 50-79 years) and there were 191 males and 181 females. Hypertension was diagnosed when the clinic BP was ≥ 140/90mm Hg on at least three occasions, or when there was a previous diagnosis of hypertension with current antihy-pertensive medication use. After potentially eligible patients were washed-out from any previous antihypertensive treatment over a period of 2 weeks, they were randomized to either of the two regiments once daily: amlodipine plus hydrochlo-rothiazide and amlodipine plus telmisartan. In order to achieve a BP goal (less than 140/90 mm Hg), the daily doses were titrated from 12.5 mg to 25 mg for hydrochlorothiazide and from 40 mg to 80 mg for telmisartan after 2 weeks. If clinic BP was still uncontrolled after 2 additional weeks, the dosage of amlodipine was increased to 5 mg daily. If clinic BP goal still did not reached, other anti-hypertensive agents including ACE inhibitor, α- or β-adrenoceptor blockers could be added at 2 months at the discretion of the investigator's opinion. All patients were monitored closely during the washout period, and an agreement was made that if any potential problem occurred, the antihypertensive treatment would be re-instated, and the patient was removed from the study. Patients were excluded if they were with any of the following conditions: secondary hypertension; major cardiovascular event; diabetes mellitus, advanced renal dysfunction; advanced hepatic or renal diseases; malignant tumor; gout; pregnancy; difficulty providing informed consent, or any other clinical conditions unsuitable for this trial.

Clinical data were collected by investigators or trained research nurses. Parameters were considered in this study as follows: age, gender, smoking, height, weight, antihypertensive agent, lipid lowering agent, clinic BP, heart rate, maximum carotid IMT, carotid stiffness index β, brachial flow-mediated dilation (FMD), serum concentration of NO, and plasma concentration of ET-1, and clinical laboratory measurements. Clinic BP was measured at baseline and at 3 monthly thereafter follow-up visits. The other parameters were assessed at baseline and annual follow-up visit. Current smoking was defined as smoking within the past year. Body mass index (BMI) = weight (kg)/height^2^ (m^2^).

Written informed consent was obtained from each patient. This study confirmed to good clinical practice guidelines and was conducted in compliance with the "Declaration of Helsinki". The Research Ethics Committee of the Shandong Academy of Medical Sciences approved this study.

Clinic BP Measurements and Definition of BP Variability
-------------------------------------------------------

Clinic BP was measured by trained research nurses using a fully automatic digital BP monitor (HEM-7071, OMRON). At each clinic visit, three consecutive measurements were obtained in sitting position with a 2-min interval after at least 5 min quiet rest and reported on the clinical research forms. The average of the three readings was adopted as the representative clinic BP value for the visit. Increasing evidences revealed that standard deviation (SD) or coefficient of variation (CV) of serial visit-to-visit BP measurements is a strong predictor of stroke, left ventricular diastolic dysfunction, cognitive dysfunction, and renal dysfunction independent of the mean value of SBP ([@ref3]--[@ref7]). Therefore, SD and CV were calculated and use to assess the VVV in BP in the present study. Maximum, minimum, and delta BP were also calculated as other parameter of the VVV in BP. CV % = SD/mean BP value × 100 (%). The delta BP = maximum BP - minimum BP.

Because 99.6% of BP measurements of all the visits (not including dropouts) for key analysis were obtained during the follow-up, above described BP parameters were calculated base on the non-missing values, and multiple imputation method was not organized in our study.

Measurement of Carotid Intima-Media Thickness and Arterial Stiffness Index β
----------------------------------------------------------------------------

Carotid artery intima-media thickness (IMT), evaluated noninvasively using high-resolution ultrasound, is widely used as a marker of early carotid atherosclerosis ([@ref13]). The common carotid arterial ultrasound was performed by one person experienced with ultrasonography using high-resolution ultrasound (Vivid *i,* GE Medical Systems Ultrasound Israel Ltd.) with a handheld 7.5MHz transducer (7.5-SPC mechanic sector transducer; GE Medical Systems Ultrasound Israel Ltd.) as previously reported ([@ref14]). Briefly, a region 1 cm proximal to the origin of the bulb of both right and left common carotid arteries was identified using B-mode ultrasound. Digital movies were recorded for 10 seconds while the patient was holding breath. IMT was measured at three different angles (anterior, lateral, and media) in both common carotid arteries from the lumen-initima interface to the collagen-containing upper layer of the adventitia. Three images of each B-mode, obtained, were recorded, digitized, and archived for subsequent analysis. The maximum of the measurements was used in the final data analysis to give maximum IMT values.

Lumen diameter (D) was measured between the luminal-intimal interface of the near wall and the far wall. Minimum (end-diastolic) and maximum (peak systolic) lumen diameters were obtained from carotid ultrasonography performed. Arterial stiffness index β, mainly used to examine the elastic properties of the carotid artery ([@ref15]), was calculated according to the following equation: stiffness index β = ln(Ps/Pd)/(\[Ds-Dd\]/Dd), where Ps is SBP, Pd is diastolic BP (DBP), and Ds and Dd are carotid systolic and diastolic diameters, respectively.

Brachial Flow-Mediated Dilation Measurement
-------------------------------------------

FMD of the brachial artery is a widely accepted clinical tool for indicating peripheral endothelial functions and subclinical atherosclerosis ([@ref16]--[@ref17]). Measurement was performed in all patients from 08:00 to 09:30 in a quiet and temperature-controlled room (20-25 °C). Smoking, caffeine, alcohol, vasoactive medications (including nitrates, ACI inhibitors, angiotensin antagonists, and calcium antagonists), anti-histamine, and anti-inflammatory medications were discontinued for 24 h, and overnight fast was also demanded before this measurements. The method of FMD measurement was used as previous studies described (1820). After at least 10 min of lying in the supine position, left brachial artery diameter was meas ured by high-resolution ultrasound (Vivid *i,* GE Medical Systems Ultrasound Israel Ltd.) with a handheld 7.5-MHz transducer (7.5-SPC mechanic sector transducer; GE Medical Systems Ultrasound Israel Ltd.) at rest and in response to increased flow. Increased flow was induced by inflation of a pneumatic tourniquet placed around the forearm to a pressure of 200 mm Hg for 5 min, followed by a release. Arterial diameter was measured at end-diastole at a fixed distance from an anatomic marker at baseline and 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5 min after cuff release. The vessel diameter in scans after reactive hyperemia was expressed as the percentage relative to baseline scan. The maximum diameter at 4 or 5 min was used to derive FMD. FMD was computed with the formula: (maximum diameter --- baseline diameter)/baseline diameterx100%. All the FMD measurements were performed by one experienced reader.

Blood Sample Collection
-----------------------

After an overnight fasting, venous blood samples of each patient were collected in the morning. Serum and plasma were separated and stored at -80°C immediately for further analysis. Each blood sample was tested in duplicate. The mean value of two measurements was used for analysis.

Nitric Oxide Measurement
------------------------

NO is an essential endogenous vasodilator, and contributes to modify the mechanical properties of the arterial wall and regulates vessel blood flow ([@ref21]) NO concentration in serum was measured by the quantification of nitrite (a stable metabolite of NO) using Griess assay ([@ref22]). In brief, 100 μ1 of serum were transferred to a flat-bottom 96-well microtiter plate and mixed with 50 μ1 of 2% sulfanilamide in 5% HCl solution and 50 μ1 of 0.1% N-(1-Naphtyl) ethylendiamine in water sequentially. To reduce nitrate to nitrite, 100 μ1 vanadium chloride III 0.8% was added to each sample and incubate at 37° for one hour. The nitrite concentration was determined by measuring optical density using an ELISA-reader (Poweam Medical Systems Co., Ltd.) in 540 nm. All samples were measured in duplicate to reduce the possibility of laboratory errors and the mean was used to analyze. All reagents were purchased from Sigma (St. Louis, MO, USA).

Endothelin-1 Measurement
------------------------

Endothelin-1 (ET-1) is a potent vasoconstrictor and plays a fundamental physiological role in the pathogenesis of atherosclerosis ([@ref23]). Plasma concentrations of ET-1 were measured by enzyme-linked immunosorbent assay (ELISA) kits following the manufacturer's instructions (Bender MedSystems, Vienna, Austria). The minimum detectable concentration was less than 1.0 pg/ml. Intra-assay and inter-assay coefficients of variation for ELISA was less than 5%. All samples were measured in duplicate.

Clinical Laboratory Measurements
--------------------------------

Total cholesterol, triglycerides, high-density lipo-protein cholesterol, low-density lipoprotein cholesterol, and fasting plasma glucose were measured by routine enzymatic laboratory methods using a Hitachi 7600 automated biochemical analyzer.

Statistical Analyses
--------------------

Statistical analysis was performed using the SPSS for Windows software package, version 17.0 (SPSS Inc., Chicago, IL, USA). Continuous data were expressed as means ± SDs or median with interquartile range (IQR, the range between the 25th and 75th percentile) depending on the normality of data. Categorical data were expressed as numbers (percentages). Because the sample size in the present study was small, for increasing the power of analysis, the tertile was selected to categorize SD for further analyses. According to the tertile of mean SD of SBP, patients were divided into three groups, namely, low SD of SBP group (low group), middle SD of SBP group (middle group), and high SD of SBP group (high group). Comparisons of maximum IMT, stiffness index β, brachial FMD, NO, and ET-1 between baseline and end of trial were evaluated by paired-samples *t* test. Comparisons of demographic, baseline clinical characteristics, and change percentages of maximum IMT, stiffness index β, FMD, NO, and ET-1 among three groups were assessed by one way analysis of variance (ANOVA) or Kruskal-Wallis test. If a significant difference was found, Bonferroni procedure with type I error was used to adjust the *P* value for multiple comparisons. Change percentages were calculated as follows: (value of measures at end of treatment period --- value of measures at baseline) / value of measures at baseline × 100 %. The chi-squared test was used to compare categorical variables among three groups. Correlations between any two continuous variables were determined using Pearson correlation coefficients, whereas categorical variables were assessed using Spearman correlation in all patients. Subsequently, stepwise multiple regression analysis was performed to select and estimate the independent effects of visit-to-visit BP variations on the change percentages of maximum IMT, stiffness index β, FMD, NO, and ET-1. Each model included following factors were considered simultaneously as independent variables: age, gender, BMI, current smoking status, baseline SBP, baseline DBP, variables of visit-to-visit variability of BP, heart rate, baseline and change percentages of blood lipid profile, baseline and change percentage fasting plasma glucose, antihy-pertensive agent, statin. Mean visit-to-visit BP was also adjusted in each model. Values of *P* \< 0.05 were considered statistically significant.

Results
=======

Characteristics of the Patients
-------------------------------

Of 372 patients, 6 died, 4 withdrew, and 6 failed to complete the study during the follow-up period, and they were excluded from the present study. Finally, 356 patients were finished 48^th^ month follow-up visit and met the criteria and were assigned to low group (*n* = 118), middle group (*n* = 120), and high group (*n* = 118), respectively, base on tertile of SD of SBP for further analysis. Mean of SD of SBP was 17.36 (SD: 10.24) mm Hg. The first tertile was less than 11.31 mm Hg, the second was from 11.32 to 18.47 mm Hg, and the third was over 18.47 mm Hg. [Figure 1](#F1){ref-type="fig"} shows the process for the recruitment of study patients. For overall, the mean age was 54.04 (SD: 7.10) years, and 47.75 % were female. The demographic, baseline clinical characteristics and treatment variables are summarized in [Table 1](#T1){ref-type="table"}. There were no differences in these variables among three groups (all *P* \> 0.05).

![The process of participants' recruitment](IJPH-43-722-g001){#F1}

###### 

Baseline demographic and clinical characteristics in overall and in three groups base on tertile of visit-to-visit variability of systolic blood pressure

  Characteristics                 Overall(*n* = 356)        Tertile of SD of SBP                                                          *X^2^* value   *F* value   *P* value
  ------------------------------- ------------------------- ------------------------- ------------------------- ------------------------- -------------- ----------- -----------
  Gender, female(%)\*             170 (47.75)               55 (46.61)                64 (53.33)                51 (43.22)                2.531                      0.282
  Age (year)^‡^                   54.04 ± 7.10              53.50 ± 6.85              53.91 ± 7.11              54.71 ± 7.40                             0.421       0.657
  BMI (kg/m^2^)^†^                25.59 (23.93, 28.04)      25.90 (23.81, 27.72)      25.59 (24.05, 28.19)      25.45 (23.93, 28.04)                                 0.978
  Smoker, *n*(%)\*                50 (14.04)                17 (14.41)                13 (10.83)                20 (16.95)                1.862                      0.394
  SBP (mm Hg)^^†^^                156.50 (149.00, 167.25)   155.75 (149.00, 164.25)   157.00 (149.50, 169.00)   156.50 (148.25, 170.00)                  0.114       0.877
  DBP (mm Hg)^^†^^                92.50 (86.50, 96.00)      91.25 (85.38, 95.50)      93.00 (86.75, 96.75)      93.50 (85.00, 96.00)                     0.141       0.843
  Heart rate (beats/min)^‡^       75.21 ± 10.38             74.80 ± 9.71              76.26 ± 8.36              74.54 ± 12.73                            0.451       0.637
  TCHO (mmol/L)                   5.54 ± 1.02               5.63 ± 1.03               5.69 ± 0.87               5.28 ± 1.11                              2.664       0.073
  TG (mmol/L)^^†^^                1.60 (1.15, 2.10)         1.60 (1.20, 2.28)         1.50 (1.20, 2.05)         1.60 (0.93, 2.10)                        0.863       0.589
  HDL-c (mmol/L)^^†^^             1.30 (1.10, 1.50)         1.30 (1.03, 1.50)         1.30 (1.20, 1.55)         1.20 (1.10, 1.40)                        1.697       0.165
  LDL-c (mmol/L)^‡^               3.11 ± 0.81               3.31 ± 0.74               3.09 ± 0.92               2.95 ± 0.73                              2.915       0.057
  FPG (mmol/L)^^†^^               5.90 (5.40, 6.50)         5.75 (5.40, 6.48)         5.80 (5.40, 6.15)         6.10 (5.53, 7.25)                        1.378       0.150
  Hydrochlorothiazide *n* (%)\*   178 (50.00)               57 (48.31)                60 (50.00)                61 (51.69)                0.271                      0.873
  CCBs *n* (%)\*                  348 (97.75)               116 (98.31)               118 (98.33)               114 (96.61)               1.049                      0.592
  ARBs *n* (%)\*                  175 (49.16)               61 (51.69)                57 (47.50)                57 (48.31)                0.470                      0.790
  Statin *n* (%)\*                128(35.96)                40 (33.90)                48 (40.00)                40 (33.90)                1.286                      0.526
  Maximum IMT (mm)^‡^             1.46 ± 0.31               1.45 ± 0.30               1.47 ± 0.31               1.45 ± 0.32                              0.093       0.911
  Stiffness index β (%)^‡^        3.50 ± 0.32               3.50 ± 0.30               3.48 ± 0.33               3.51 ± 0.33                              0.182       0.834
  FMD (%) ^‡^                     8.25 ±2.64                8.51±2.49                 8.10±2.69                 8.14±2.77                                0.419       0.658
  NO (μmol/L)^‡^                  59.06 ± 7.99              58.28 ± 8.87              60.00 ± 7.71              58.88 ± 7.36                             0.668       0.514
  ET-1 (pg/ml)^‡^                 40.93 ± 6.32              40.07 ± 6.50              40.91 ± 6.36              41.81 ± 6.09                             1.055       0.350

Results are mean ± standard deviation or medians (25

th

, 75

th

percentiles)./Abbreviation: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TCHO, total cholesterol; TG, triglycerides; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; FPG, fasting plasma glucose; ; CCB, calcium channel blocker; ARB, angiotensin receptor blocker; IMT, intima-media thickness; FMD, flow-mediated dilation; NO, nitric oxide; ET-1, endothelin-1./\*Chi-square test;

†

Kruskal-Wallis tests;

‡

one way analysis of variance.

Univariate Correlations of Visit-to-Visit Variability in Systolic Blood Pressure with Change Percentages of Carotid Maximum Intima-Media Thickness, Arterial Stiffness Index β, Brachial Flow-Mediated Dilation, Nitric Oxide, and Endothelin-1 in Overall
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We evaluated the correlations of VVV in SBP with change percentages of maximum IMT, stiffness index β, FMD, NO, and ET-1 in overall ([Table 2](#T2){ref-type="table"}). Change percentages of maximum IMT and ET-1 were positively correlated with SD, CV, maximum, delta, and mean of SBP (*P* \< 0.05). Change percentage of stiffness index β was positively correlated with SD, CV, maximum, and delta, and negatively correlated with minimum SBP (*P* \< 0.05). Change percentages of FMD and NO were negatively correlated with SD, CV, maximum, delta, and mean of SBP (*P* \< 0.05).

###### 

Pearson correlation coefficients of variability in systolic blood pressure with change percentages of carotid artery measures and endothelial function measures

                                               SD of SBP (mm Hg)   CV of SBP (%)   Max SBP (mm Hg)   Min SBP (mm Hg)   Delta SBP (mm Hg)                                     
  -------------------------------------------- ------------------- --------------- ----------------- ----------------- ------------------- ------- -------- ------- -------- -------
  Change percentage of maximum IMT(%)          0.647               0.000           0.647             0.000             0.421               0.000   -0.011   0.917   0.473    0.000
  Change percentage of stiffness index β (%)   0.640               0.000           0.637             0.000             0.431               0.000   -0.234   0.028   0.607    0.000
  Change percentage of FMD (%)                 -0.683              0.000           -0.683            0.000             -0.473              0.000   0.044    0.683   -0.502   0.000
  Change percentage of NO (%)                  -0.715              0.000           -0.704            0.000             -0.529              0.000   0.188    0.079   -0.662   0.000
  Change percentage of ET-1 (%)                0.554               0.000           0.540             0.000             0.432               0.000   -0.040   0.714   0.434    0.000

Abbreviation: SBP, systolic blood pressure; SD, standard deviation; CV, coefficient of variation; max, maximum; min, minimum; IMT, intima-media thickness; FMD, flow-mediated dilation; NO, nitric oxide; ET-1, endothelin-1.

Univariate Correlations of Visit-to-Visit Variability in Diastolic Blood Pressure with Change Percentages of Carotid Maximum Intima-Media Thickness, Arterial Stiffness Index β, Brachial Flow-Mediated Dilation, Nitric Oxide, and Endothelin-1 in Overall
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We also assessed the correlations of VVV in DBP with change percentages of maximum IMT, stiffness index β, FMD, NO, and ET-1 in overall. [Table 3](#T3){ref-type="table"} reveals the correlation coefficients. Change percentage of maximum IMT was positively correlated with mean and delta DBP (*P* \< 0.05). Change percentages of stiffness index β and ET-1 positively correlated with SD and CV of DBP and delta DBP (*P* \< 0.05). Change percentages of FMD and NO were negatively correlated with SD and CV of DBP, and delta and maximum DBP (*P* \< 0.05).

###### 

Pearson correlation coefficients of variability in diastolic blood pressure with change percentages of carotid artery measures and endothelial function measures

                                               SD of DBP (mm Hg)   CV of DBP (%)   Max DBP   Min DBP (mm Hg)   Delta DBP (mm Hg)                                     
  -------------------------------------------- ------------------- --------------- --------- ----------------- ------------------- ------- -------- ------- -------- -------
  Change percentage of maximum IMT (%)         0.125               0.105           0.135     0.080             0.075               0.336   -0.111   0.151   0.171    0.026
  Change percentage of stiffness index β (%)   0.176               0.022           0.181     0.019             0.048               0.538   -0.133   0.084   0.163    0.034
  Change percentage of FMD (%)                 -0.245              0.001           -0.247    0.001             -0.178              0.021   0.045    0.563   -0.219   0.004
  Change percentage of NO (%)                  -0.183              0.017           -0.185    0.016             -0.156              0.043   0.068    0.381   -0.217   0.005
  Change percentage of ET-1 (%)                0.179               0.020           0.185     0.016             0.169               0.028   -0.053   0.493   0.217    0.005

Abbreviation: DBP, diastolic blood pressure; SD, standard deviation; CV, coefficient of variation; max, maximum; min, minimum; IMT, intima-media thickness; FMD, flow-mediated dilation; NO, nitric oxide; ET-1, endothelin-1.

Multiple regression analysis
----------------------------

To investigate the potential independently factors associated with change percentages of maximum IMT, stiffness index β, FMD, NO, and ET-1, the multivariate analysis with stepwise was performed ([Table 4](#T4){ref-type="table"}). In the models, change percentages of maximum IMT, stiffness index β, FMD, NO, and ET-1 were dependent variables, respectively. Independent variables were variables that that significantly correlated with change percentage of maximum IMT, stiffness index β, FMD, NO, or ET-1 as determined by Pearson's or Spearman's correlation analysis or were considered as potential confounding factors as described in Statistical analyses section. Mean BP was also adjusted in each model. For change percentage of maximum IMT, there were statistical results for SD and CV of SBP. For change percentage of stiffness index β, there were significant results for SD and CV of SBP, and change percentage of LDL-c. For change percentage of FMD, there were significant results for SD and CV of SBP, change percentage of TG, and baseline LDL-c. For change percentage of NO, there were significant results for SD and CV of SBP, and delta SBP. For change percentage of ET-1, there were significant results for SD and CV of SBP, change percentage of TG, and statin treatment. However, most importantly, SD and CV of SBP were always statistically associated with change percentage of maximum IMT, stiffness index β, FMD, NO, and ET-1.

###### 

Stepwise linear regression of the coefficient of factors independently associated with change percentages of carotid artery measures and endothelial function measures over the on-treatment period \*

  Trait                        Change percentage of maximum IMT (%)   Change percentagee of stiffness index β(%)   Change percentage of FMD (%)   Change percentage of NO (%)   Change percentage of ET-1 (%)                                                                             
  ---------------------------- -------------------------------------- -------------------------------------------- ------------------------------ ----------------------------- ------------------------------- ---------- ------------------------- ---------- ------------------------- ----------
  SD of SBP                    0.665 (0.545, 0.785)                   \< 0.001                                     1.388 (1.139, 1.638)           \< 0.001                      -0.905 (-1.053, -0.756)         \< 0.001   -2.314 (-2.660, -1.986)   \< 0.001   0.993 (0.761, 1.224)      \< 0.001
  CV of SBP                    0.874 (0.716, 1.031)                   \< 0.001                                     1.815 (1.486, 2.144)           \< 0.001                      -1.176 (-1.375, -0.978)         \< 0.001   -1.479 (-2.900, -0.058)   0.041      1.285 (0.961, 1.556)      \< 0.001
  Change percentage of LDL-c   \--                                    \--                                          0.080 (0.010, 0.151)           0.025                         \--                             \--        \--                       \--        \--                       \--
  Delta SBP                    \--                                    \--                                          \--                            \--                           \--                             \--        -0.320 (-0.604, -0.058)   0.027      \--                       \--
  Change percentage of TG      \--                                    \--                                          \--                            \--                           0.101 (0.020, 0.182)            0.015      \--                       \--        -0.126 (-0.249, -0.003)   0.044
  Baseline LDL-c               \--                                    \--                                          \--                            \--                           0.489 (0.021, 0.975)            0.041      \--                       \--        \--                       \--
  Statin                       \--                                    \--                                          \--                            \--                           \--                             \--        \--                       \--        -1.761 (-2.957, -0.564)   0.004

Abbreviation: B, unstandardized regression coefficient; IMT, intima-media thickness; FMD, flow-mediated dilation; NO, nitric oxide; ET-1, endo-thelin-1; SBP, systolic blood pressure; SD, standard deviation; CV, coefficient of variation; TG, triglycerides; LDL-c, low-density lipoprotein cholesterol.

\*Factors included as potentially independent variables were age, gender, BMI, current smoking status, baseline SBP, baseline DBP, variables of visit-to-visit variability of BP, heart rate, baseline and change percentages of blood lipid profile, baseline and change percentage fasting plasma glucose, antihypertensive treatment agent, statin. Mean visit-to-visit BP was also adjusted in each model.

Changes of carotid maximum intima-media thickness and arterial stiffness index β in overall and three groups
------------------------------------------------------------------------------------------------------------

[Figure 2](#F2){ref-type="fig"} reveals the change percentages of maximum IMT ([Fig. 2A](#F2){ref-type="fig"}) and stiffness index β ([Fig. 2B](#F2){ref-type="fig"}) during the on-treatment period in overall and three groups.

![Change percentages of carotid IMT (A) and stiffness index β (B) during the on-treatment period in overall and three groups. Change percentages of carotid IMT and stiffness index β were determined base on the tertile of mean SD of SBP. Results are medians (*horizontal bars* in *boxes)* and 25^th^ and 75^th^ percentiles (*lower and upper error bars,* respectively). IMT, intima-media thickness. \**P* \< 0.05 compared to baseline, †*P* \< 0.05 compared to low group, ‡-*P* \< 0.05 compared to middle group](IJPH-43-722-g002){#F2}

Compared to baseline, maximum IMT elevated in overall \[mean difference -0.014, 95% confidence interval (CI) -0.020 to -0.008, *P* \< 0.05\] and high group (mean difference -0.042, 95% CI -0.050 to -0.033, *P* \< 0.05), decreased in low group (mean difference 0.008, 95% CI 0.000 to 0.016, *P* \< 0.05), and was no significant change in middle group. Change percentage of maximum IMT \[Median (IQR)\] was -0.70 (-2.26, 0.72) % in low group, 0.69 (-1.09, 2.37) % in middle group, and 2.98 (1.39, 4.70) % in high group. There were significant differences between any two groups (*F* = 39.833, *P* \< 0.05).

Compared with baseline, stiffness index β was significantly decreased in overall and three groups. Median (IQR) change percentage of stiffness index β was -11.68 (-14.25, -8.06) %, -8.00 (-10.71, -4.00) %, and -3.00 (-6.00, -0.07) % in from low group to high group, respectively. The decreased percentage of stiffness index β in lower groups was statistically greater than in higher group (*F* = 47.135, *P* \< 0.05).

Changes of brachial flow-mediated dilation, nitric oxide, and endothelin-1 in overall and three groups
------------------------------------------------------------------------------------------------------

[Figure 3](#F3){ref-type="fig"} demonstrates the change percentages of brachial FMD ([Fig. 3A](#F3){ref-type="fig"}), NO ([Fig. 3B](#F3){ref-type="fig"}), and ET-1 ([Fig. 3C](#F3){ref-type="fig"}) during the on-treatment period in overall and three groups.

![Change percentages of brachial FMD (A), NO (B), and ET-1 (C) during the on-treatment period in overall and three groups. Change percentages of FMD, NO, and ET-1 were determined base on the tertile of mean SD of SBP. Results are medians (*horizontal bars* in *boxes)* and 25^th^ and 75^th^ percentiles (*lower and upper error bars,* respectively). FMD, flow-mediated dilation; NO, nitric oxide; ET-1, endothelin-1. \**P* \< 0.05 compared to baseline, †*P* \< 0.05 compared to low group, ‡*P* \< 0.05 compared to middle group](IJPH-43-722-g003){#F3}

Compared to baseline, FMD and NO were statistically increased, and ET-1 was statistically decreased in overall and three groups. Median (IQR) change percentage of FMD was 8.50 (6.57, 9.51) %, 6.30 (4.80, 8.32) %, and 2.47 (0.56, 4.63) %, NO was 25.54 (21.73, 30.45) %, 20.88 (16.25, 25.48) %, 12.92 (7.45, 19.69) %, and ET-1 was -8.59 (-11.00, -5.95) %, -7.00 (-10.18, -4.00) %, -2.00 (-5.00, 0.40) % in from low group to high group, respectively. The increased percentages of FMD (*F* = 58.612, *P* \< 0.05) and NO (*F* = 45.648, *P* \< 0.05) in lower groups were statistically greater than in higher groups. For the decreased percentage of ET-1, it was markedly lower in high group than in low (mean difference -1.554, 95% CI -3.344 to 0.237, *P* \< 0.05) and middle group (mean difference -4.509, 95% CI -6.299 to -2.718, *P* \< 0.05); there was no difference between low group and middle group (*P* \> 0.05).

Discussion
==========

In this study, we evaluated relationships between VVV in BP and the progression of atherosclerosis and endothelial dysfunction in on-treated essential hypertensive patients. The major findings were those, 1) decreased percentages of carotid maximum IMT, stiffness index β, and ET-1, and increased percentages of brachial FMD and NO in lower groups base on the tertile of SD of SBP were significant greater than in higher groups, 2) change percentages of maximum IMT, stiffness index β, FMD, NO, and ET-1 were significantly correlated with measures of VVV in BP, especially VVV in SBP, 3) SD and CV of SBP were risk factors for IMT, stiffness index β, FMD, NO, and ET-1 independently of other influential factors, such as mean SBP and DBP, baseline SBP and DBP.

SD and CV of Serial SBP Measurement
-----------------------------------

Either SD or CV of SBP is on behalf of the deviation of SBP from the mean, and is recognized to be static over time ([@ref24]). Levitan et al. ([@ref25]) reported that there was a strong correlation between SD of SBP and CV of SBP (r = 0.99) and they convey the similar information. In this respect, patients were only categorized by tertile of SD of SBP, although CV of SBP was used to other analysis such as univariate correlations and multiple regression analysis.

Visit-to-Visit Variability of BP and Target Organ Damage
--------------------------------------------------------

The primary goals of antihypertensive treatment are to protect against the development and progression of subclinical organ damage, and to directly prevent cardiovascular events ([@ref26]). Studies have shown the BP variability, independently of mean BP, associated with increased risk of early atherosclerosis ([@ref27]), target organ damage ([@ref28]), and cardiovascular events ([@ref29]). However, VVV in SBP is usually dismissed as an obstacle to a limitation of measuring BP in the office setting and the reliable estimation of usual BP ([@ref30]).

Studies ([@ref6], [@ref31]) reported that VVV in BP to be a powerful predictor of all-cause mortality in patients with type 2 diabetes. Subjects in the middle and highest tertiles of VVV in SBP had greater risk of all-cause mortality than subjects in the lowest tertile of VVV in SBP ([@ref6]). In the high risk elderly, excessive VVV in BP was a significant indicator for carotid artery atherosclerosis and stiffness independently of mean BP ([@ref32]). In an animal study ([@ref33]), using sinoaortic-denervation (SAD) rats, high BP variability was revealed to be one of an important cause of impaired endothelial function. BP variability closely correlated with FMD and the vascular smooth muscle response to NO independent of age, body mass index and mean BP levels in African Americans ([@ref10]).

In our study, consistent with the above researches, progression of IMT, stiffness index β, ET-1, FMD, and NO correlated with measures of VVV in BP, especially SD and CV of SBP. After controlled for potential confounders including age, visit-to-visit mean SBP and DBP, baseline SBP and DBP, and antihypertensive therapy, SD and CV of SBP were always risk factors for progression of carotid IMT, stiffness index β, FMD, NO, and ET-1 independently.

However, results of European Lacidipine Study on Atherosclerosis (ELSA) ([@ref34]) using post-hoc analysis shown that mean on-treatment clinic or 24-h SBP, not CV or SD of SBP was associated with carotid IMT evolution. In a study of healthy individuals followed-up over a 12-year period, VVV in SBP did not contribute to risk stratification beyond mean SBP ([@ref35]). This maybe due to some reasons such as predominantly disease-free participants, short duration of trial, and less cardiovascular outcomes ([@ref5], [@ref36]).

Limitation and Further Direction
================================

There were also several limitations to our study. Firstly, as the present study was part of the CHIEF study, our sample size was small. This may induce some bias in the study. Secondly, the study patients were only recruited in Chinese population; therefore, it is uncertain whether our findings are generalized in other ethnic groups. Thirdly, fluctuations of BP can be influenced by several factors such as autonomic nervous system, lifestyle, as well as atherosclerosis ([@ref26], [@ref37]). The function of autonomic nervous system and lifestyle were not included in the study. Fourthly, medication possession ratio of patients was not included in the present study, although it was greater than 97.50%. Finally, eight patients exclusion from the analyses might have introduced a bias in this study. Therefore, more, large and further prospective trials are necessarily needed.

Conclusion
==========

Our study documents that excessive VVV in SBP maybe increase carotid atherosclerosis, impair en-dothelial function, and reduce the benefit of anti-hypertensive treatment in on-treated essential hypertensive patients. Reducing visit-to-visit BP fluctuation might be regarded as a potentially essential therapeutic target in patients with hypertension management.
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